[144] Arcutis Biotherapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) has submitted a Form 144 notifying the SEC of an intended sale of 9,208 common shares by insider Howard Welgus. The shares are to be brokered through Merrill Lynch on or about 01 July 2025 and carry an aggregate market value of roughly $127,431. With 119,201,724 shares outstanding, the contemplated transaction represents approximately 0.008 % of the float.

The stock being sold originates from three restricted-stock vesting events: 06 Jun 2023 (2,583 sh), 27 Feb 2024 (2,250 sh) and 31 May 2024 (4,375 sh). The filing also discloses previous dispositions by the same insider over the past three months—10,000 shares on 01 May 2025 for $146,357 and 10,139 shares on 18 Jun 2025 for $135,269—bringing total recent insider sales to 29,347 shares valued at $409,057.

No additional operational, earnings or strategic information is provided; the document solely fulfills Rule 144 notice obligations for this limited insider sale.

Insights

Securities Analyst

TL;DR: Limited Form 144 sale—9,208 shares, ~0.008 % of float; signal effect minimal, overall neutral.

The filing reveals a modest planned disposition by Howard Welgus following two earlier sales this quarter. In dollar terms (~$127k) and share terms (~0.008 % of shares outstanding), the event is immaterial to capital structure and liquidity. While continued insider selling can influence sentiment, the volumes involved are far below thresholds that typically affect supply-demand dynamics or valuation multiples. No operational data accompanies the notice, so the transaction appears routine for tax or diversification purposes. I therefore classify the impact as neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr 5th Flr Columbus OH 43240	9208	127431.00	119201724	07/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/01/2023	Restricted stock vest	Arcutis Biotherapeutics Inc			2583	06/01/2023	NA
Common	02/27/2024	Restricted stock vest	Arcutis Biotherapeutics Inc			2250	02/27/2024	NA
Common	05/31/2024	Restricted stock vest	Arcutis Biotherapeutics Inc			4375	05/31/2024	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Welgus 3027 Townsgate rd, Suite 300 Westlake Village CA 91361	Common	05/01/2025	10000	146357.00
Howard Welgus 3027 Townsgate rd, Suite 300 Westlake Village CA 91361	Common	06/18/2025	10139	135269.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)